Geode Capital Management
MIRM icon

Geode Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Geode Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163M Buy
1,393,908
+133,905
+11% +$13.4M 0.01% 916
2026
Q1 		$116M Buy
1,260,003
+197,077
+19% +$18.5M 0.01% 989
2025
Q4 		$84M Buy
1,062,926
+52,904
+5% +$3.8M 0.01% 1197
2025
Q3 		$74.1M Sell
1,010,022
-19,594
-2% -$1.25M ﹤0.01% 1242
2025
Q2 		$52.4M Buy
1,029,616
+65,951
+7% +$2.94M ﹤0.01% 1394
2025
Q1 		$43.4M Buy
963,665
+20,321
+2% +$958K ﹤0.01% 1457
2024
Q4 		$39M Buy
943,344
+7,147
+0.8% +$298K ﹤0.01% 1591
2024
Q3 		$36.5M Buy
936,197
+29,017
+3% +$1.16M ﹤0.01% 1633
2024
Q2 		$31M Buy
907,180
+210,041
+30% +$5.51M ﹤0.01% 1681
2024
Q1 		$17.5M Buy
697,139
+15,959
+2% +$439K ﹤0.01% 2004
2023
Q4 		$20.1M Buy
681,180
+106,100
+18% +$3.21M ﹤0.01% 1922
2023
Q3 		$18.2M Buy
575,080
+49,518
+9% +$1.36M ﹤0.01% 1879
2023
Q2 		$13.6M Buy
525,562
+107,348
+26% +$2.85M ﹤0.01% 2103
2023
Q1 		$10M Buy
418,214
+18,532
+5% +$422K ﹤0.01% 2248
2022
Q4 		$7.79M Buy
399,682
+20,180
+5% +$399K ﹤0.01% 2422
2022
Q3 		$7.97M Buy
379,502
+98,642
+35% +$2.37M ﹤0.01% 2397
2022
Q2 		$5.46M Buy
280,860
+84,422
+43% +$1.99M ﹤0.01% 2656
2022
Q1 		$4.33M Buy
196,438
+23,545
+14% +$480K ﹤0.01% 2880
2021
Q4 		$2.76M Sell
172,893
-3,780
-2% -$58.8K ﹤0.01% 3211
2021
Q3 		$3.52M Buy
176,673
+2,402
+1% +$39.1K ﹤0.01% 3116
2021
Q2 		$3.01M Buy
174,271
+1,841
+1% +$33K ﹤0.01% 3142
2021
Q1 		$3.42M Buy
172,430
+60,218
+54% +$1.15M ﹤0.01% 2966
2020
Q4 		$1.96M Buy
112,212
+2,285
+2% +$44.9K ﹤0.01% 3100
2020
Q3 		$2.12M Buy
109,927
+5,387
+5% +$116K ﹤0.01% 2851
2020
Q2 		$2.03M Buy
104,540
+11,182
+12% +$187K ﹤0.01% 2826
2020
Q1 		$1.31M Buy
93,358
+34,790
+59% +$571K ﹤0.01% 2898
2019
Q4 		$1.44M Buy
58,568
+37,510
+178% +$400K ﹤0.01% 3142
2019
Q3 		$211K Buy
+21,058
New +$258K ﹤0.01% 3745

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management's MIRM Position: Q2 2026 in Review

Geode Capital Management increased its Mirum Pharmaceuticals (MIRM) stake by 11% in Q2 2026, buying an estimated $13.4M and bringing the position to 1,393,908 shares worth $163M. The position accounts for 0.01% of the portfolio, ranked #916.

Geode Capital Management first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Geode Capital Management held 1,393,908 shares of Mirum Pharmaceuticals worth $163M as of Q2 2026.
  • Geode Capital Management bought 133,905 Mirum Pharmaceuticals shares in Q2 2026, an estimated $13.4M.
  • Mirum Pharmaceuticals made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #916 holding.
  • Geode Capital Management first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.